Concordant with our previous results demonstrating that inhibition of the MET pathway in U87 tumors result in EGFR pathway activation [14], this study support a biological reciprocity between the two pathways and provides additional evidence for the combined use of MET and EGFR inhibitors in treating GBM patients with EGFRamp. The gene discussed is MET; the disease is glioblastoma.